FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approves a supplemental application for the combination product spironolactone and hydrochlorothiazide, manufactured by Prasco Laboratories, under NDA 01261…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Edema
• Heart Failure
• Hypertension
• Nephrotic Syndrome

Drugs mentioned

• Spironolactone and Hydrochlorothiazide (Spironolactone; Hydrochlorothiazide)

Snippet

SUPPL AP for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE)